Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > 2.39 ASK

<< Previous

Bullboard Posts

Next >>

Comment by Bertie20on Oct 14, 2021 4:29pm

98 Views

Post# 34006852

RE:RE:RE:RE:RE:RE:RE:RE:RE:2.39 ASK

Thanks GoldenArm! I saw your recommendation for Arch on the DME board, checked it out, and went with it. So many thanks for the heads up!

The way Arch is going, I can see its share price surpassing DME's quite soon. I love the risk:reward potential on this one, but it's pretty tense waiting for these peer-reviewed phase II results. It's alot like waiting for the result of a helium exploration well!

<< Previous

Bullboard Posts

Next >>

Defence Therapeutics touts anticancer treatment and immune booster